CLINICAL UROLOGY: Original ArticlesTransdermal Application of Verapamil Gel to the Penile Shaft Fails to Infiltrate the Tunica Albuginea

[1]  T. Shankey,et al.  Basic fibroblast growth factor expression in Peyronie's disease. , 2001, The Journal of urology.

[2]  C. Riedl,et al.  Iontophoresis for treatment of Peyronie's disease. , 2000, The Journal of urology.

[3]  Y. Kalia,et al.  TRANSDERMAL DRUG DELIVERY: Clinical Aspects , 1998 .

[4]  L. Levine.  Treatment of Peyronie's disease with intralesional verapamil injection. , 1997, The Journal of urology.

[5]  R. Dahiya,et al.  Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. , 1997, The Journal of urology.

[6]  G. Jordan,et al.  Proposal: trauma as the cause of the Peyronie's lesion. , 1996, The Journal of urology.

[7]  R. Vosshenrich,et al.  Sexual dysfunction in Peyronie's disease: an analysis of 222 patients without previous local plaque therapy. , 1997, The Journal of urology.

[8]  R. Jewelewicz.  New developments in topical estrogen therapy. , 1997, Fertility and sterility.

[9]  G. Bottazzo,et al.  The immunological features of Peyronie's disease. , 1996, The Journal of urology.

[10]  T. Lue,et al.  Is colchicine effective in Peyronie's disease? A pilot study. , 1994, Urology.

[11]  M. Roberts,et al.  Iontophoretic transdermal delivery of salicylic acid and lidocaine to local subcutaneous structures. , 1993, Journal of pharmaceutical sciences.

[12]  G. Bottazzo,et al.  The treatment of Peyronie's disease with tamoxifen. , 1992, British journal of urology.

[13]  Raphael C Lee,et al.  Calcium antagonists retard extracellular matrix production in connective tissue equivalent. , 1990, The Journal of surgical research.

[14]  W. Scott,et al.  THE USE OF TOCOPHEROLS IN THE TREATMENT OF PEYRONIE'S DISEASE , 1949 .